RxDoctor Payments Data

Jena Pizula, MD

Cardiovascular Disease · Stanford, CANPI 1326401621

Payments from drug & device makers

$2,878in general payments, 2019–2025

Across 35 payments — averaging $82.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$635
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$457
  • Abbott$410
  • Edwards Lifesciences$355
  • Vifor Pharma, Inc.$183
  • Bardy Diagnostics, Inc.$121
  • plus $716 from 11 others

What the payments were for

  • Grants$2509%
  • Food & beverage$2,62791%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,878 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$94,796
Medicare patients
565
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$84,482
EntrestoSacubitril/Valsartan67$71,470
EliquisApixaban36$43,645
XareltoRivaroxaban18$20,909
Rosuvastatin Calcium109$2,518
Ezetimibe33$2,211
Droxidopa13$2,129
Atorvastatin Calcium107$1,204
Metoprolol Succinate66$1,007
Propranolol Hcl25$562
Losartan Potassium59$517
Spironolactone50$419
Furosemide73$403
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide34$383
Carvedilol29$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$66$71,47067 claims
PfizerEliquis$12$43,64536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →